Skip to content
HowShorted

C4 Therapeutics, Inc. short interest in 2022

In 2022, C4 Therapeutics, Inc.'s disclosed short interest ran from 6.43% of shares outstanding on 14 Jan 2022 to 7.16% on 30 Dec 2022, a change of +0.73 percentage points. The year's high was 11.02% on 14 Apr 2022 and its low 5.59% on 31 Jan 2022, averaging 8.99% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 19.21 days on 31 Aug 2022. Full history: C4 Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for C4 Therapeutics, Inc. in 2022

2022 in figures

Start of year
6.43% (14 Jan 2022)
End of year
7.16% (30 Dec 2022)
Change
+0.73 pp
High
11.02% (14 Apr 2022)
Low
5.59% (31 Jan 2022)
Average
8.99%
Highest days to cover
19.21 (31 Aug 2022)
SEC filings marked
9

Every report in 2022

C4 Therapeutics, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20226.43%8.07results (8-K)
31 Jan 20225.59%4.45
15 Feb 20226.89%7.19
28 Feb 20227.49%10.4310-K filed, results (8-K)
15 Mar 20229.71%8.41
31 Mar 202210.53%7.85
14 Apr 202211.02%1.92
29 Apr 202210.48%6.23
13 May 20227.99%4.6110-Q filed, results (8-K)
31 May 20228.80%6.05
15 Jun 20228.63%7.46
30 Jun 202210.40%4.29
15 Jul 202210.71%12.42
29 Jul 202210.83%13.49
15 Aug 202210.49%14.8210-Q filed, results (8-K)
31 Aug 20229.96%19.21
15 Sep 20229.27%11.23
30 Sep 202210.30%6.46
14 Oct 202210.11%13.54
31 Oct 20229.96%15.54
15 Nov 20228.07%6.8210-Q filed, results (8-K)
30 Nov 20227.42%7.85
15 Dec 20227.43%11.40
30 Dec 20227.16%5.42

See also: C4 Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.